The Medical Letter on Drugs and Therapeutics
Mepolizumab (Nucala) for Severe Eosinophilic Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 5/1/18: Information in the Dosage section regarding hypersensitivity reactions was revised.

The FDA has approved mepolizumab (Nucala - GSK), a subcutaneously injected humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for maintenance treatment of severe asthma in patients ≥12 years old who have an eosinophilic phenotype.

EOSINOPHILIC PHENOTYPE — Severe asthma has been defined as asthma that can only be controlled with high-dose inhaled glucocorticoids plus a second controller medication and/or systemic glucocorticoids, or that remains uncontrolled despite this therapy. What constitutes an eosinophilic phenotype is not well defined, but patients in this category generally have severe disease with high eosinophil levels in blood and sputum despite treatment with a glucocorticoid.1

MECHANISM OF ACTION — IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, and activation of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Mepolizumab (Nucala) for Severe Eosinophilic Asthma
Article code: 1486e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian